ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that Jetrea (ocriplasmin) has gained approval in Brazil.

Jetrea has been indicated for the treatment of adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

If left untreated, VMT generally leads to significant visual distortion, deterioration in visual acuity, or even central blindness. With Jetrea, retina physicians in Brazil will have access to the world’s first and only pharmacological treatment option for VMT, allowing them to intervene earlier and potentially stop the progression of this debilitating disease.

ThromboGenics’ partner Alcon, which is commercializing Jetrea outside the US, will be responsible for the launch of the drug in Brazil.

Jetrea (ocriplasmin) is a truncated form of human plasmin. In the US, Jetrea is indicated for the treatment of symptomatic VMA. In Europe, Jetrea is indicated for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. Jetrea is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion.

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines.